Activated Protein C

Directory of Therapeutic Enzymes

Volumn , Issue , 2005, Pages 69-95

  Grinnell, Brian W ^a   Yan, S Betty ^a   Macias, William L ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85179209972     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1201/9781420038378-4     Document Type: Chapter

References (222)

1. Beckmann, R.J., et al., The structure and evolution of a 461 amino acid human protein C precursor and its messenger RNA, based upon the DNA sequence of cloned human liver cDNAs, Nucleic Acids Res., 13, 5233-5247, 1985.
2. Foster, D.C., et al., Propeptide of human protein C is necessary for gamma-carboxylation, Biochemistry, 26, 7003-7011, 1987.
3. Drakenberg, T., et al., α-Hydroxyaspartic acid in vitamin K-dependent protein C., Proc. Natl. Acad. Sci. USA, 80, 1802-1806, 1983.
4. Grinnell, B.W., Walls, J.D., and Gerlitz, B., Glycosylation of human protein C affects its secretion, processing, functional activities and activation by thrombin, J. Biol. Chem., 226, 9778-9785, 1991.
5. Miletich, J.P. and Broze, G.J., Beta protein C is not glycosylated at asparagine 329, J. Biol. Chem., 265, 11397-11404, 1990.
6. Harris, R.J. and Spellman, M.W., O-linked fucose and other post-translational modifications unique to EGF modules, Glycobiology, 3, 219-224, 1993.
7. McClure, D.B., Walls, J.D., and Grinnell, B.W., Post-translational processing events in the secretion pathway of human protein C, a complex vitamin K-dependent antithrombotic factor, J. Biol. Chem., 267, 19710-19717, 1992.
8. Yan, S.C.B., Grinnell, B.W., and Wold, F., Post-translational modifications of protein: Some problems left to solve, Trends Biochem. Sci., 14, 264-268, 1989.
9. Yan, S.B., et al., Characterization and novel purification of recombinant human protein C from three mammalian cell lines, Bio/Technology, 8, 655-661, 1990.
10. Gerlitz, B., et al., Effect of mutation of Asp71 on human protein C activation and function, J. Cell. Biochem., 14E, 201, 1990.
11. Grinnell, B.W., et al., Native and modified recombinant human protein C: Function secretion and posttranslational modifications, in Protein C and Related Anticoagulants, Bruley, D. and Drohan, W., Eds., Gulf Publishing Co., Houston, 1990, pp. 13-46.
12. Grinnell, B.W., Hermann, R.B., and Yan, S.B., Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide, Glycobiology, 4, 221-225, 1994.
13. Grinnell, B.W., et al., Trans-activated expression of fully gamma-carboxylated recombinant human protein C, an antithrombotic factor, Bio/Technology, 5, 1189-1192, 1987.
14. Grinnell, B.W., et al., Expression and characterization of fully functional recombinant human protein C from the human kidney cell line 293, in Current Advances in Vitamin K Research, Suttie, J.W., Ed., Elsevier, New York, 1988, pp. 191-198.
15. Fisher, B.E., and Will, H., Effects of intact fibrin and partially plasmin-degraded fibrin on kinetic properties of one-chain tissue plasminogen activator, Biochem. Biophys. Acta, 1041, 48-54, 1990.
16. Suttie, J.W., Report of workshop on expression of vitamin K-dependent proteins in bacterial and mammalian cells, Thromb. Res., 44, 129-134, 1986.
17. Oppenheimer, C. and Wydro, R., Cellular Processing of Vitamin K-Dependent Proteins, Suttie, J.W., Ed., Elsevier, New York, 1988.
18. Anson, D.S., Austen, D.E.G., and Brownlee, G.G., Expression of active human clotting factor IX from recombinant DNA clones in mammalian cells, Nature, 315, 683-685, 1985.
19. de la Salle, H., et al., Active gamma-carboxylated human factor IX expressed using recombinant DNA techniques, Nature, 316, 268-270, 1985.
20. Busby, S., et al., Expression of active human factor IX in transfected cells, Nature, 316, 271-273, 1985.
21. Graham, F.L., Transformation by and Oncogenicity of Human Adenoviruses, Ginsberg, H.S., Ed., Plenum Press, New York, 1984, pp. 631-639.
22. Berg, D.T., et al., Viral transformation increases vitamin K-dependent gamma-carboxylation of glutamate, Exp. Cell Res., 192, 32-40, 1991.
23. Berg, D.T., Walls, J., and Grinnell, B.W., A variant enhancer/regulatory region from a cloned human prototype BK virus genome, Nucleic Acids Res., 16, 9057, 1988.
24. Berg, D.T., et al., E1A-induced enhancer activity of the poly(dG-dT).poly(dA-dC) element (GT element) and interactions with a GT-specific nuclear factor, Mol. Cell. Biol., 9, 5248-5253, 1989.
25. Berg, D.T., McClure, D.B., and Grinnell, B.W., E1a-responsive mammalian host/vector system for the stable high-level expression of secreted proteins, Nucleic Acids Res., 20, 5485-5486, 1992.
26. Berg, D.T., McClure, D.B., and Grinnell, B.W., High-level expression of secreted proteins from cell adapted to serum-free suspension culture, Biotech., 6, 972-978, 1993.
27. Walls, J.D. and Grinnell, B.W., A rapid and versatile method for the detection and isolation of mammalian cell lines secreting recombinant proteins, Biotechniques, 8, 138-142, 1990.
28. Walls, J.D., et al., Amplification of multicistronic plasmids in the human 293 cell line and secretion of correctly processed recombinant human protein C, Gene, 81, 139-149, 1989.
29. Yan, S.B., Review of conformation-specific affinity purification methods for plasma vitamin Kdependent proteins, J. Mol. Recognition, 9, 211-218, 1996.
30. Foster, D.C., et al., Endoproteolytic processing of the dibasic cleavage site in the human protein C precursor in transfected mammalian cells: Effects of sequence alterations on efficiency of cleavage, Biochemistry, 29, 347-354, 1990.
31. Kisiel, W., Human plasma protein C: Isolation, characterization, and mechanism of activation by alpha-thrombin, J. Clin. Invest., 64, 761-769, 1979.
32. Cumming, D.A., Glycosylation of recombinant protein therapeutics: Control and functional implications, Glycobiology, 1, 115-130, 1991.
33. Yan, S.B., Chao, Y.B., and van Halbeek, H., Novel Asn-linked oligosaccharides terminating in GalNAc(1-4)[Fucα(1-3)]GalNAc(1-2) are present in recombinant human protein C expressed in human kidney 293 cells, Glycobiology, 3, 597-608, 1993.
34. Chan, A.L., et al., A novel sialylated N-acetylgalactosamine-containing oligosaccharide is the major complex-type structure present in Bowes melanoma tissue plasminogen activator, Glycobiology, 1, 173-185, 1991.
35. Bergwerff, A.A., et al., Human urokinase contains GalNAc(1-4)[Fucα(1-3)]GlcNAc(1-2) as a novel terminal element in N-linked carbohydrate chains, FEBS Lett., 314, 389-394, 1992.
36. Tomiya, N., et al., Structural elucidation of a variety of GalNAc-containing N-linked oligosaccharides from human urinary kallidinogenase, J. Biol. Chem., 268, 113-126, 1993.
37. Dell, A., et al., Structural analysis of the oligosaccharide derived from glycodelin, a human glycoprotein with potent immunosuppresive and contraceptive activities, J. Biol. Chem., 270, 24116-24126, 1995.
38. Gruber, A., et al., Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial athrombosis, Circulation, 82, 578-585, 1990.
39. Morris, H., et al., Gender-specific glycosylation of human glycodelin affects its contraceptive activity, J. Biol. Chem., 271, 32159-32167, 1996.
40. van den Nieuwenhof, I., et al., Recombinant glycodelin carrying the same type of glycan structure as contraceptive glycodelin-A can be produced in human kidney 293 cells but not in Chinese hamster ovary cells, Eur. J. Biochem., 267, 4753-4762, 2000.
41. De Graaf, T.W., et al., Inflammation-induced expression of sialyl Lewis X-containing Glycan structures on α1-acid glycoprotein (orosomucoid) in human sera, J. Exp. Med., 177, 657-666, 1993.
42. Walz, G., et al., Recognition by ELAM-1 of the sialys-LeX determinant on myeloid and tumor cell, Science, 250, 1132-1135, 1990.
43. Yan, S.B., Chao, B.Y., and van Halbeek, H., Novel oligosaccharide structures on recombinant human protein C expressed in human kidney 293 cells, J. Cell Biochem., 16D, 151, 1992.
44. Yan, S.B. and Grinnell, B.W., Recombinant human protein C, protein S and thrombomodulin as antithrombotics, Perspective Drug Discovery Des., 1, 503-520, 1994.
45. Yan, S.B. and Grinnell, B.W., Antithrombotic and anti-inflammatory agents of the protein C anticoagulant pathway, Ann. Rep. Med. Chem., 11, 103-112, 1994.
46. Bernard, G., et al., Safety and dose-relationship of recombinant human activated protein C (rhAPC) on coagulopathy in severe sepsis, Crit. Care Med., 29, 2051-2059, 2001.
47. Bernard, G., et al., Efficacy and safety of recombinant human activated protein C for severe sepsis, New Engl. J. Med., 344, 699-705, 2001.
48. Ehrlich, H.J., et al., Direct expression of recombinant activated human protein C, a serine protease, J. Biol. Chem., 264, 14298-14304, 1989.
49. Richardson, M.A., Gerlitz, B., and Grinnell, B.W., Charge reversal at the P3' position in protein C optimally enhances thrombin affinity and activation rate, Protein Sci., 3, 711-712, 1994.
50. Ehrlich, H.J., et al., Recombinant human protein C derivatives: Altered response to calcium resulting in enhanced activation by thrombin, EMBO J., 9, 2367-2373, 1990.
51. Richardson, M.A., Gerlitz, B., and Grinnell, B.W., Enhancing protein C interaction with thrombin results in a clot-activated antcoagulant, Nature, 360, 261-264, 1992.
52. Rezaie, A.R., et al., Mutation of Glu 80 to Lys results in a protein C mutant, that no longer requires Ca2for rapid activation by the thrombin-thrombomodulin complex, J. Biol. Chem., 269, 3151-3154, 1994.
53. Rezaie, A.R. and Esmon, C.T., The function of calcium in protein C activation by thrombin and thrombin-thrombomodulin complex can be distinguished by mutational analysis of protein C derivatives, J. Biol. Chem., 267, 26104-26109, 1992.
54. Kurz, K.D., et al., Antithrombotic efficacy in the guinea pig of a derivative of human protein C with enhanced activation by thrombin, Blood, 89, 534-540, 1997.
55. Glasscock, N.L., et al., Basic residues in the 37-loop of activated protein C modulate inhibition by protein C inhibitor but not by alpha (1)-antitrypsin, Biochim. Biophys. Acta, 1647, 106-117, 2003.
56. Berg, D.T., et al., Engineering the proteolytic specificity of activated protein C improves its pharmacological properties, Proc. Natl. Acad. Sci. USA, 100, 4423-4428, 2003.
57. Kurz, K.D., et al., Comparison in an arteriovenous (AV) shunt model of thrombosis in the guinea pig of the antithrombotic and anticoagulant activities of a gla-domain variant of human activated Protein C (APC) with native APC and with a low molecular weight heparin (LMWH), Blood, 100, 281a, 2002.
58. Shen, L., et al., Enhancement of human protein C function by site-directed mutagenesis of the gamma-carboxyglutamic acid domain, J. Biol. Chem., 273, 31086-31091, 1998.
59. Nelsestuen, G., Enhancement of vitamin-K-dependent protein function by modification of the gamma-carboxyglutamic acid domain: Studies of protein C and factor VII, Trends Cardiovasc. Med., 9, 162-167, 1999.
60. Esmon, C.T., The protein C anticoagulant pathway, Arterioscler. Thromb., 12, 135-145, 1992.
61. Esmon, C.T., Molecular events that control the protein C anticoagulant pathway, Thromb. Haemostas., 70, 29-35, 1993.
62. Esmon, C.T. and Schwarz, H.P., An update on clinical and basic aspects of the protein C anticoagulant pathway, Trends Cardiovasc. Med., 5, 141-148, 1995.
63. Esmon, C.T., et al., The protein C pathway: New insights, Thromb. Haemostas., 78, 70-74, 1997.
64. Esmon, C., The protein C pathway, Crit. Care Med., 28 (Suppl. 9), S44-48, 2000.
65. Esmon, C.T., et al., Inflammation, sepsis, and coagulation, Haematologica, 84, 254-259, 1999.
66. Grinnell, B.W. and Yan, S.B., Novel antithrombotics based on modulation of the protein C pathway, Coron. Artery Dis., 9, 89-97, 1998.
67. Horrevoets, A.J., et al., Vascular endothelial genes that are responsive to tumor necrosis factoralpha in vitro are expressed in atherosclerotic lesions, including inhibitor of apoptosis protein-1, stannin, and two novel genes, Blood, 93, 3418-3431, 1999.
68. Grinnell, B. and Joyce, D.E., Recombinant human activated protein C: A system modulator of vascular function for treatment of severe sepsis, Crit. Care Med., 29, S53-S61, 2001.
69. Joyce, D.E. and Grinnell, B.W., Recombinant human activated protein C attenuates the inflammatory response in endothelium and monocytes by modulating nuclear factor-kappaB, Crit. Care Med., 30, S288-293, 2002.
70. Joyce, D.E., et al., Gene expression profile of antithrombotic protein C defines new mechanisms modulating inflammation and apoptosis, J. Biol. Chem., 276, 11199-11203, 2001.
71. Riewald, M., et al., Activation of endothelial cell protease activated receptor 1 by the protein C pathway, Science, 296, 1880-1882, 2002.
72. Vervloet, M., Thijs, L., and Hack, C., Derangements of coagulation and fibrinolysis in critically ill patients with sepsis and septic shock, Semin. Thromb. Hemostas., 24, 33-44., 1998.
73. Bajzar, L., Manuel, R., and Nesheim, M.E., Purification and characterization of TAFI, a throminactivable fibrinolysis inhibitor, J. Biol. Chem., 270, 14477-14484, 1995.
74. Bajzar, L., Fredenburgh, J.C., and Nesheim, M., The activated protein C-mediated enhancement of tissue-type plasminogen activator-induced fibrinolysis in a cell-free system, J. Biol. Chem., 265, 16948-16954, 1990.
75. Bajzar, L., Nesheim, M., and Tracy, P.B., The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent, Blood, 88, 2093-2100, 1996.
76. Jackson, C., Bailey, B., and Shetler, T., Pharmacological profile of recombinant, human activated protein C (LY203638) in a canine model of coronary artery thrombosis, J. Pharmacol. Exp. Ther., 295, 967-971, 2000.
77. Jackson, C.V., et al., Recombinant human activated protein C (LY203638) induced reperfusion in a canine model of occlusive coronary artery thrombosis, Circulation, 98, I454, 1998.
78. Esmon, C.T., et al., Regulation and functions of the protein C anticoagulant pathway, Haematologica, 84, 363-368, 1999.
79. Coughlin, S.R., et al., Characterization of a functional thrombin receptor: Issues and opportunities, J. Clin. Invest., 89, 351-355, 1992.
80. Hancock, W.W., and Bach, F.H., Immunobiology and therapeutic applications of protein C/protein S/thrombomodulin in human and experimental allotransplantation and xenotransplantation, Trends Cardiovasc. Med., 7, 174-183, 1997.
81. Grey, S.T. and Hancock, W.W., Inhibition of LPS-induced activation of human monocytes by activated protein C (APC) occurs through a novel mechanism, J. Leukocyte Biol., 114 A487, 1993.
82. Grey, S., et al., Selective effects of protein C on activation of human monocytes by lipopolysaccharide, interferon-gamma or PMA: Modulation of effects on CD11b and CD14 but not CD25 or CD54 induction, Transplant. Proc., 25, 2913-2914, 1993.
83. Grey, S.T., et al., Selective inhibitory effects of the anticoagulant activated protein C on the responses of human monocuclear phagocytes to LPS, IFN-, or phorbol ester, J. Immunol., 153, 3664-3672, 1994.
84. Taylor, F.B., et al., Protein C prevents the coagulopathic and lethal effects of E. coli infusion in the baboon, J. Clin. Invest., 79, 918-925, 1987.
85. Hancock, W.W., et al., The anticoagulants protein C and protein S display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy, Transplantation Proc., 24, 2302-2303, 1992.
86. Dhainaut, J.F., et al., Drotrecogin alfa (activated) (recombinant human activated protein C) reduces host coagulopathy response in patients with severe sepsis, Thromb. Haemostas., 90 (4), 642-653, 2003.
87. Derhaschnig, U., et al., Recombinant human activated protein C (rhAPC; drotrecogin alfa [activated]) has minimal effect on markers of coagulation, fibrinolysis, and inflammation in acute human endotoxemia, Blood, 102, 2093-2098, 2003.
88. Kalil, A., et al., Effects of drotrecogin alfa (activated) in human endotoxemia, Shock, 21, 222-229, 2004.
89. Schmide-Supprian, M., et al., Activated protein C inhibits tumor necrosis factor and macrophage migration inhibitory factor production in monocytes, Eur. Cytokine Network, 11, 407-413, 2000.
90. White, B., et al., Activated protein C inhibits lipopolysaccharide-induced nuclear translocation of nuclear factor kappaB (NF-kappaB) and tumour necrosis factor alpha (TNF-alpha) production in the THP-1 monocytic cell line, Br. J. Haematol., 110, 130-134, 2000.
91. Mosnier, L.O. and Griffin, J.H., Inhibition of staurosporine-induced apoptosis of endothelial cells by activated protein C requires protease activated receptor-1 and endothelial cell protein C receptor, Biochem. J., 8, 65-70, 2003.
92. Cheng, T., et al., Activated protein C blocks p53-mediated apoptosis in ischemic human brain endothelium and is neuroprotective, Nat. Med., 9, 338-342, 2003.
93. Laszik, Z., et al., Human protein C receptor is present primarily on endothelium of large blood vessels: Implications for the control of the protein C pathway, Circulation, 96, 3633-3640, 1997.
94. Guo, H., et al., Activated protein C prevents neuronal apoptosis via protease activated receptors 1 and 3, Neuron, 41, 563-572, 2004.
95. Joyce, D.E., Nelson, D.R., and Grinnell, B.W., Leukocyte and endothelial interactions in sepsis:Relevance of the Protein C pathway, Crit. Care Med., 32 (Suppl.5), S280-S286, 2004.
96. Sturn, D.H., et al., Expression and function of the endothelial protein C receptor in human neutrophils, Blood, 102, 1499-1505, 2003.
97. Feistritzer, C., et al., Endothelial protein C receptor-dependent inhibition of human eosinophil chemotaxis by protein C, J. Allergy Clin. Immunol., 112, 375-381, 2003.
98. Gruber, A., et al., Inhibition of platelet-dependent thrombus formation by human activated protein C in a primate model, Blood, 73, 639-642, 1989.
99. Hanson, S.R., et al., Antithrombotic effects of thrombin-induced activation of endogenous protein C in primates, J. Clin. Invest., 92, 2003-2012, 1993.
100. Araki, H., et al., Inhibitory effects of activated protein C and heparin on thrombotic arterial occlusion in rat mesenteric arteries, Thromb. Res., 62, 209-216, 1991.
101. Arnlijots, B., Bergqvist, D., and Dahlback, B., Inhibition of microarterial thrombosis by bovine activated protein C in a rabbit model, Thromb. Haemostas., 69, (Abstr.), 589, 1993.
102. Emerick, S.C., et al., Preclinical pharmacology of activated protein C, in The Pharmacology and Toxicology of Proteins, J.S. Holcenberg and J.L. Winkelhake, Eds., Anal R. Liss, Inc., New York, 1987, pp. 351-367.
103. Wakefield, T.W., et al., Deep venous thrombosis in the baboon: An experimental model, J. Vasc. Surg., 14, 588-598, 1991.
104. McBane, R., et al., Antithrombotic action of endogenous porcine protein C activated with a latent porcine thrombin preparation, Thromb. Haemostas., 74, 879-885, 1995.
105. Sakamoto, T., et al., Prevention of arterial reocclusion after thrombolysis with activated protein C: Comparison with heparin in a canine model of coronary artery thrombosis, Circulation, 90, 427-432, 1994.
106. Yamashita, T., et al., The antithrombotic effect of human activated protein C on He-Ne laserinduced thrombosis in rat mesenteric microvessels, Thromb. Res., 75, 33-40, 1994.
107. Smirnov, M., et al., Low doses of activated protein C delay arterial thrombosis in rats, Thromb. Res., 57, 645-650, 1991.
108. Romisch, J., et al., Activated protein C: Antithrombotic properties and influence on fibrinolysis in an animal model, Fibrinolysis, 5, 191-196, 1991.
109. Krishnamurti, C., et al., Enhancement of tissue plasminogen activator-induced fibrinolysis by activated protein C in endotoxin-treated rabbits, J. Lab. Clin. Med., 118, 523-530, 1991.
110. Gruber, A., et al., Antithrombotic effects of combining activated protein C and urokinase in nonhuman primates, Circulation, 84, 2454-2462, 1991.
111. Clouse, L.H. and Comp, P.C., The regulation of hemostasis: The protein C system, New Engl. J. Med., 314, 1298-1304, 1986.
112. Auberger, K., Evaluation of a new protein C concentrate and comparison of protein C assays in a child with congenital protein C deficiency, Ann. Hematol., 64, 146-151, 1992.
113. De Stefano, V., et al., Replacement therapy with a purified protein C concentrate during initiation of oral anticoagulation in severe protein C congenital deficiency, Thromb. Haemostas., 70, 247-249, 1993.
114. Dreyfus, M., et al., Treatment of homozygous protein C deficiency and neonatal purpura fulminans with purified protein C concentrate, New Engl. J. Med., 325, 1565-1568, 1991.
115. Lewandowski, K. and Zawilska, K., New approach to the treatment of warfarin-induced skin necrosis in the protein C deficiency, Thromb. Haemostas., 69, (Abstr.), 725, 1993.
116. Manco-Johnson, M. and Nuss, R., Protein C concentrate prevents peripartum thrombosis, Am. J. Hematol., 40, 69-70, 1992.
117. Schramm, W., et al., Treatment of coumarin-induced skin necrosis with a monoclonal antibody purified Protein C concentrate, Arch. Dermatol., 129, 753-759, 1993.
118. Schwarz, H.P., et al., Acute and long-term treatment of severe congenital protein C deficiency with protein C concentrate, Thromb. Haemostas., 69, (Abstr.), 1020, 1993.
119. Dreyfus, M., et al., Replacement therapy with a monoclonal antibody purified protein C concentrate in newborns with severe congenital Protein C deficiency, Semin. Thromb. Haemostas., 21, 371-381, 1995.
120. Muller, F.M., et al., Purpura fulminans in severe congenital protein C deficiency: Monitoring of treatment with protein C concentrate, Eur. J. Pediatr., 155, 20-25, 1996.
121. Wada, H., Deguch, K., and Shirakawa, S., Successful treatment of deep vein thrombosis in homozygous protein C deficiency with activated protein C, Am. J. Hematol., 44, 218-219, 1993.
122. Wada, H., Shirakawa, S., and Shiku, H., Multicenter trail of plasma-derived activated protein C concentrate (CTC-111) in patients with venous thrombosis associated with inherited protein C deficiency, Blood, 94, 111, 1999.
123. Nakayama, T., et al., A case of purpura fulminans is caused by homozygous 8857 mutation (protein C-Nagoya) and successfully treated with activated protein C concentrate, Br. J. Haematol., 110, 727-730, 2000.
124. Manco-Johnson, M. and Knapp-Clevenger, R., Activated protein C concentrate reverses purpura fulminans in severe genetic protein C deficiency, J. Pediatric Hematology/Oncology, 26 (1), 25-27, 2004.
125. Aoki, N., A phase III clinical study of a plasma derived human activated protein C for the treatment of DIC, J. New Remedies Clinics, 47, 448-482, 1998.
126. Kobayashi, T., et al., Activated protein C is effective for disseminated intravascular coagulation associated with placental abruption, Thromb. Haemostas., 82, 1363, 1999.
127. Okajima, K., et al., Treatment of patients with disseminated intravascular coagulation by protein C, Am. J. Hematol., 33, 277-278, 1990.
128. Okajima, K., et al., Effect of protein C and activated protein C on coagulation and fibrinolysis in normal human subjects, Thromb. Haemostas., 63, 48-53, 1990.
129. Sakamoto, T., et al., Effect of activated protein C on plasma plasminogen activator inhibitor activity in patients with acute myocardial infarction treated with alteplase, J. Am. Coll. Cardiol., 42, 1389-1394, 2003.
130. Oh, H., et al., Activated protein C (APC) for the prevention and treatment of veno-occlusive disease (VOD) of the liver after bone marrow transplantation (BMT), Blood, 92, 325b, 1998.
131. Oda, Y., Tsumoto, K., and Mizokami, H., Inhibitory effect of activated protein C on the experimental cerebral infarction in rabbits, Thromb. Haemostas., 69, (Abstr.), 724, 1993.
132. Shibata, M., et al., Anti-inflammatory, antithrombotic, and neuroprotective effects of activated protein C in a murine model of focal ischemic stroke, Circulation, 103, 1799-1805, 2001.
133. Murakami, K., et al., Activated protein C attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats, Blood, 87, 642-647, 1996.
134. Mizutani, A., et al., Activated protein C reduces ischemia/reperfusion-induced renal injury in rats by inhibiting leukocyte activation, Blood, 95, 3781-3787, 2000.
135. Snow, T.R., et al., Protein C activation following coronary artery occlusion in the in situ porcine heart, Circulation, 84, 293-299, 1991.
136. Natanson, C., Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment, Crit. Care Med., 25, 1095-1100, 1997.
137. Zeni, F., Freeman, B., and Natanson, C., Anti-inflammatory therapies to treat sepsis and septic shock: A reassessment, Crit. Care Med., 25, 1095-1100, 1997.
138. Brun-Buisson, C., et al., Incidence, risk factors and outcome of severe sepsis and septic shock in adults, JAMA, 274, 968-974, 1995.
139. Abraham, E., Therapies for sepsis emerging therapies for sepsis and septic shock, West J. Med., 166, 195-200, 1997.
140. Sands, K., et al., Epidemiology of sepsis syndrome in 8 academic medical centers, JAMA, 278, 234-240, 1997.
141. Friedman, G., Silva, E., and Vincent, J.-L., Has the mortality of septic shock changed with time?, Crit. Care Med., 26, 2078-2086., 1998.
142. Natanson, C., Esposito, C., and Banks, S., The sirens’ songs of confirmatory sepsis trials:Selection bias and sampling error, Crit. Care Med., 26, 1927-1931, 1998.
143. Linde-Zwirble, W., et al., Age-specific incidence and outcome of sepsis in the US, Crit. Care. Med., 27, 33, 1999.
144. Opal, S. and Cohen, J., Clinical Gram-positive sepsis: Does it fundamentally differ from Gramnegative bacterial sepsis?, Crit. Care Med., 27, 1608-1616, 1999.
145. Bone, R.C., The pathogenesis of sepsis, Ann. Intern. Med., 115, 457-469, 1991.
146. Wheeler, A.P. and Bernard, G.R., Treating patients with severe sepsis, New Engl. J. Med., 340, 207-214, 1999.
147. Hesselvik, J.F., et al., Protein C, protein S and C4b-binding protein in severe infection and septic shock, Thromb. Haemostas., 65, 126-129, 1991.
148. Kidokoro, A., et al., Alterations in coagulation and fibrinolysis during sepsis, Shock, 5, 223-228, 1996.
149. Levi, M., et al., The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxaemia, Eur. J. Clin. Invest., 27, 3-9, 1997.
150. Carvalho, A.C. and Freeman, N.J., How coagulation defects alter outcome in sepsis: Survival may depend on reversing procoagulant conditions, J. Crit. Illness, 9, 51-75, 1994.
151. Fisher, C.J. and Yan, S.B., Protein C levels as a prognostic indicator of outcome in sepsis and related diseases, Crit.Care Med., 28, S49-S56, 2000.
152. Matthay, M., Severe sepsis-a new treatment with both anticoagulant and antiinflammatory properties, New Engl. J. Med., 344, 759-762, 2001.
153. Hotchkiss, R. and Karl, I.E., The pathophysiology and treament of sepsis, New Engl. J. Med., 348, 138-150, 2003.
154. Coughlin, S.R., Sol Sherry lecture in thrombosis: How thrombin ‘talks’ to cells: Molecular mechanisms and roles in vivo, Arterioscler. Thromb. Vasc. Biol., 18, 514-518, 1998.
155. Aird, W.C., The role of the endothelium in severe sepsis and multiple organ dysfunction syndrome, Blood, 101, 3765-3777, 2003.
156. Esmon, C., Inflammation and thrombosis. Mutual regulation by protein C, Immunologist, 6, 84-89, 1998.
157. Astiz, M. and Rackow, E., Septic shock, Lancet, 351, 1501-1505, 1998.
158. Lorente, J., et al., Time course of hemostatic abnormalities in sepsis and its relation to outcome, Chest, 103, 1536-1542, 1993.
159. Iba, T., Kidokoro, A., and Yagi, Y., The role of the endothelium in changes in procoagulant activity in sepsis, J. Am. Coll. Surg., 187, 321-329, 1998.
160. Levi, M. and ten Cate, H., Disseminated intravascular coagulation, New Engl. J. Med., 341, 586-592, 1999.
161. McGilvray, I.D. and Rotstein, O.D., Role of the coagulation system in the local and systemic inflammatory response, World J. Surg., 22, 179-186, 1998.
162. Hotchkiss, R., et al., Sepsis-induced apoptosis causes progressive profound depletion of B and CD4T lymphocytes in humans, J. Immunol., 166, 6952-6963, 2001.
163. Papathanassoglou, E.D., Moynihan, J.A., and Ackerman, M.H., Does programmed cell death (apoptosis) play a role in the development of multiple organ dysfunction in critically ill patients? A review and a theoretical framework, Crit. Care Med., 28 (2), 537-549, 2000.
164. Stefanec, T., Endothelial apoptosis: Could it have a role in the pathogenesis and treatment of disease?, Chest, 117, 841-854, 2000.
165. Mahidhara, R. and Billiar, T.R., Apoptosis in sepsis, Crit. Care Med., 28 (Suppl. 4), N105-113, 2000.
166. Bombeli, T., et al., Apoptotic vascular endothelial cells become procoagulant, Blood, 89, 2429-2442, 1997.
167. Faust, S., et al., Dysfunction of endothelial protein C activation in severe meningococcal sepsis, New Engl. J. Med., 345, 408-416, 2001.
168. Conway, E.M. and Rosenberg, R.D., Tumor necrosis factor suppresses transcription of the thrombomodulin gene in endothelial cells, Mol. Cell. Biol., 8, 5588-5592, 1988.
169. Takano, S., et al., Plasma thrombomodulin in health and diseases, Blood, 76, 2024-2029, 1990.
170. Moore, K.L., Esmon, C.T., and Esmon, N.L., Tumor necrosis factor leads to the internalization and degradation of thrombomodulin from the surface of bovine aortic endothelial cells in culture, Blood, 73, 159-165, 1989.
171. Levi, M., et al., Pathogenesis of disseminated intravascular coagulation in sepsis, JAMA, 270, 975-979, 1993.
172. Mesters, R.M., et al., Increase of plasminogen activator inhibitor levels predicts outcome of leukocytopenic patients with sepsis, Thromb. Haemostas., 75, 902-907, 1996.
173. Bajzar, L., Nesheim, M.E., and Tracy, P.B., The profibrinolytic effect of activated protein C in clots formed from plasma is TAFI-dependent, Blood, 88, 2093-2100, 1996.
174. Bajzar, L., Morser, J., and Nesheim, M., TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thromobmodulin complex, J. Biol. Chem., 271, 16603-16608, 1996.
175. Roman, J., et al., Protein C, protein S and C4b-binding protein in neonatal severe infection and septic shock, J. Perinat. Med., 20, 111-116, 1992.
176. Fourrier, F., et al., Septic shock, multiple organ failure and disseminated intravascular coagulation:Compared patterns of antithrombin III, protein C and protein S deficiencies, Chest, 101, 816-823, 1992.
177. Leclerc, F., et al., Protein C and S deficiency in severe infectious purpura of children: A collaborative study of 40 cases, Intensive Care Med., 18, 202-205, 1992.
178. Alcaraz, A., et al., Activation of the protein C pathway in acute sepsis, Thromb. Res., 79, 83-93, 1995.
179. Fijnvandraat, K., et al., Coagulation activation and tissue necrosis in meningococcal septic shock:Severely reduced protein C levels predict a high mortality, Thromb. Haemostas., 73, 15-20, 1995.
180. Massignon, D., et al., Coagulation/fibrinolysis balance in septic shock related to cytokines and clinical state, Haemostas., 24, 36-48, 1994.
181. Wuillemin, W.A., et al., Activation of the intrinsic pathway of coagulation in children with meningococcal septic shock, Thromb. Haemostas., 74, 1436-1441, 1995.
182. Mesters, R., et al., Prognostic value of protein C levels in Neutropenic patients at high risk of severe septic complications, Crit. Care Med., 28, 2209-2216, 2000.
183. Yan, S., et al., Low levels of protein C are associated with poor outcome in severe sepsis, Chest, 120, 915-922, 2001.
184. Mesters, R., et al., Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients, Blood, 88, 881-886, 1996.
185. Mammen, E., The haematological manifestations of sepsis, J. Antimicrob. Chemother., 41 (Suppl. A), 17-24, 1998.
186. Mesters, R.M., et al., Factor VIIa and antithrombin III activity during severe sepsis and septic shock in neutropenic patients, Blood, 88, 881-886, 1996.
187. Hairo, W.D., et al., Multiple organ dysfunction syndrome in bone marrow transplantation, JAMA, 274, 1289-1295, 1995.
188. Taylor, F.B. Jr., et al., Protein C prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon, J. Clin. Invest., 79, 918-925, 1987.
189. Taylor, F.B., et al., DEFR-Factor Xa blocks disseminated intravascular coagulation initiated by E. coli without preventing shock or organ damage, Blood, 78, 364-368, 1991.
190. Rivard, G.E., et al., Treatment of purpura fulminans in meningococcemia with protein C concentrate, J. Pediatr., 126, 646-652, 1995.
191. Rintala, E., et al., Protein C in the treatment of coagulopathy in meningococcal disease, Lancet, 347, 1767, 1996.
192. Smith, O.P., White, B., and Rafferty, M., Successful treatment of meningococcal induced protein C deficiency/purpura fulminans in children with protein C concentrate and heparin, Thromb. Haemostas., 97, 419, 1997.
193. Powars, D., et al., Epidemic meningococcemia and purpura fulminans with induced protein C deficiency, Clin. Infectious Disease, 17, 254-261, 1993.
194. Rintala, E., et al., Protein C in the treatment of coagulopathy in meningococcal disease, Crit. Care Med., 26, 965-968, 1998.
195. Esmon, C.T., Introduction: Are natural anticoagulants candidates for modulating the inflammatory response to endotoxin?, Blood, 95, 1113-1116, 2000.
196. Smith, K., et al., Purpura fulminans and S. pneumonia sepsis with severe acquired protein C deficiency successfully treated with recombinant human activated protein C, Thromb. Hemostas. (Suppl.82), 731, 1999.
197. Rintala, E., et al., Protein C substitution in sepsis-associated purpura fulminans, Crit. Care Med., 28, 2373-2378, 2000.
198. Gerson, W.T., et al., Severe acquired protein C deficiency in purpura fulminans associated with disseminated intravascular coagulation: Treatment with protein C concentrate, Pediatrics, 91, 418-422, 1993.
199. deKleijn, E., et al., Activation of protein C following infusion of protein C concentrate in children with severe meningococcal sepsis and purpura fulminans: A randomized, doubleblinded, placebo-controlled, dose-finding study, Crit. Care Med., 31, 1839-1847, 2003.
200. Yan, S. and Dhainaut, J.F., Only activated protein C treatment and not protein C has demonstrated an improvement in survival in severe sepsis, Crit Care Med 32, 2004.
201. Redl, H., et al., Expression of endothelial leukocyte adhesion molecule-1 in septic but not traumatic/hypovolemic shock in the baboon, Am. J. Pathol., 139, 461-466, 1991.
202. Newman, W., et al., Soluble E-selectin is found in supernatants of activated endothelial cells and is elevated in the serum of patients with septic shock, J. Immunol., 150, 644-654, 1993.
203. Bevilacqua, M.P. and Nelson, R.M., Selectins, J. Clin. Invest., 91, 379-387, 1993.
204. Kukielka, G.L., et al., Induction of myocardial ELAM-1 by ischemia and reperfusion, FASEB J., 6, 1060A, 1992.
205. Rosenberg, R. and Aird, W., Vascular-bed-specific hemostasis and hypercoagulable states, New Engl. J. Med., 340, 1555-1564, 1999.
206. Krishnaswamy, G., et al., Human endothelium as a source of multifunctional cytokines:Molecular regulation and possible role in human disease, J. Interferon Cytokine Res., 19, 91-104, 1999.
207. Gonzalez-Amaro, A. and Sanchez-Madrid, F., Cell adhesion molecules: Selectins and integrens, Crit. Reviews Immunol., 19, 389-429, 1999.
208. Pohlman, T. and Harlan, J., Adaptive response of the endothelium to stress, J. Surg. Res., 89, 85-119, 2000.
209. Angus, D., et al., Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care, Crit. Care Med., 29, 1303-1310, 2001.
210. Bernard, G.R., et al., Recombinant human activated protein C (rhAPC) produces a trend toward improvement in morbidity and 28 day survival in patients with severe sepsis, Crit. Care Med., 27, S4, 1999.
211. Fisher, C.J., et al., Recombinant human activated protein C (rhAPC) improves coagulation abnormalities, morbidity and 28 day mortality in patients with severe sepsis, J. Antimicrob. Chemother., 44 (Suppl. A), 10, 1999.
212. Ely, E.W., et al., Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis, Crit. Care Med., 31, 12-19, 2003.
213. Vincent, J.L., et al., Effects of drotrecogin alfa (activated) on organ dysfunction in the PROWESS trial, Crit. Care Med., 31, 834-840, 2003.
214. Macias, W.L., Yan, S.B., and Grinnell, B.W., The development of drotrecogin alfa (activated) for the treatment of severe sepsis, Int. J. Artificial Organs, 27, 360-370, 2004.
215. Bernard, G.R., et al., Safety assessment of drotrecogin alfa (activated) in the treatment of adult patients with severe sepsis, Crit. Care (London), 7, 155-163, 2003.
216. Warren, B.L., et al., Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: A randomized controlled trial, JAMA, 286, 1869-1878, 2001.
217. Abraham, E., Reinhart, K., and Opal, S., Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis; A randomized controlled trial, JAMA, 290, 238-247, 2003.
218. Macias, W.L., et al., Pharmacokinetic-pharmacodynamic analysis of drotrecogin alfa (activated) in patients with severe sepsis, Clin. Pharmacol. Therapeut., 72, 391-402, 2002.
219. Kerlin, B., et al., Survival advantage associated with heterozygous factor V Leiden mutation in patients with severe sepsis and in mouse endotoxemia, Blood, 102, 3085-3092, 2003.
220. Aird, W., Thrombin paradox redux, Blood, 102, 3077-3078, 2003.
221. Dellinger, R., et al., Surviving sepsis campaign guidelines for management of severe sepsis and septic shock, Crit. Care Med., 32, 858-873, 2004.
222. Grinnell, B.W., Hermann, R.B., and Yan, S.B., Human protein C inhibits selectin-mediated cell adhesion: Role of unique fucosylated oligosaccharide, Glycobiology, 4, 221-225, 1994.